|
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
RECRUITINGSponsored by Boryung Pharmaceutical Co., Ltd
Actively Recruiting
SponsorBoryung Pharmaceutical Co., Ltd
Started2023-07-26
Est. completion2025-10-21
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05970237
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Eligibility
Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria: * Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab. * Those who voluntarily signed a written personal information agreement to participate in this clinical study. * Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion. Exclusion Criteria: * Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.) * Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1) * Those who are expected to need insulin prescription during the study period * Pregnant women, breast-feeding women
Conditions3
DiabetesDiabetes MellitusHypertension
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorBoryung Pharmaceutical Co., Ltd
Started2023-07-26
Est. completion2025-10-21
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05970237